Literature DB >> 18988906

Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema.

Madeleine Austinat1, Stefan Braeuninger, João B Pesquero, Marc Brede, Michael Bader, Guido Stoll, Thomas Renné, Christoph Kleinschnitz.   

Abstract

BACKGROUND AND
PURPOSE: Brain edema is detrimental in ischemic stroke and its treatment options are limited. Kinins are proinflammatory peptides that are released during tissue injury. The effects of kinins are mediated by 2 different receptors (B1 and B2 receptor [B1R and B2R]) and comprise induction of edema formation and release of proinflammatory mediators.
METHODS: Focal cerebral ischemia was induced in B1R knockout, B2R knockout, and wild-type mice by transient middle cerebral artery occlusion. Infarct volumes were measured by planimetry. Evan's blue tracer was applied to determine the extent of brain edema. Postischemic inflammation was assessed by real-time reverse-transcriptase polymerase chain reaction and immunohistochemistry. To analyze the effect of a pharmacological kinin receptor blockade, B1R and B2R inhibitors were injected.
RESULTS: B1R knockout mice developed significantly smaller brain infarctions and less neurological deficits compared to wild-type controls (16.8+/-4.7 mm(3) vs 50.1+/-9.1 mm(3), respectively; P<0.0001). This was accompanied by a dramatic reduction of brain edema and endothelin-1 expression, as well as less postischemic inflammation. Pharmacological blockade of B1R likewise salvaged ischemic tissue (15.0+/-9.5 mm(3) vs 50.1+/-9.1 mm(3), respectively; P<0.01) in a dose-dependent manner, even when B1R inhibitor was applied 1 hour after transient middle cerebral artery occlusion. In contrast, B2R deficiency did not confer neuroprotection and had no effect on the development of tissue edema.
CONCLUSIONS: These data demonstrate that blocking of B1R can diminish brain infarction and edema formation in mice and may open new avenues for acute stroke treatment in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18988906     DOI: 10.1161/STROKEAHA.108.526673

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  52 in total

1.  HOE-140, an antagonist of B2 receptor, protects against memory deficits and brain damage induced by moderate lateral fluid percussion injury in mice.

Authors:  Ana Paula Oliveira Ferreira; Fernanda Silva Rodrigues; Iuri Domingues Della-Pace; Bibiana Castagna Mota; Sara Marchesan Oliveira; Camila de Campos Velho Gewehr; Franciane Bobinski; Clarissa Vasconcelos de Oliveira; Juliana Sperotto Brum; Mauro Schneider Oliveira; Ana Flavia Furian; Claudio Severo Lombardo de Barros; Adair Roberto Soares dos Santos; Juliano Ferreira; Michele Rechia Fighera; Luiz Fernando Freire Royes
Journal:  Psychopharmacology (Berl)       Date:  2013-11-08       Impact factor: 4.530

Review 2.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

3.  Early Increased Bradykinin 1 Receptor Contributes to Hemorrhagic Transformation After Ischemic Stroke in Type 1 Diabetic Rats.

Authors:  Hongfei Sang; Zhongming Qiu; Jin Cai; Wenya Lan; Linjie Yu; Hao Zhang; Min Li; Yi Xie; Ruibing Guo; Ruidong Ye; Xinfeng Liu; Ling Liu; Renliang Zhang
Journal:  Transl Stroke Res       Date:  2017-07-19       Impact factor: 6.829

4.  Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.

Authors:  Sigurdur T Sigurdsson; Olaf B Paulson; Arne Høj Nielsen; Svend Strandgaard
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-11       Impact factor: 6.200

5.  The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice.

Authors:  Raimund Trabold; Christian Erös; Klaus Zweckberger; Jane Relton; Heike Beck; Juerg Nussberger; Werner Müller-Esterl; Michael Bader; Eric Whalley; Nikolaus Plesnila
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-23       Impact factor: 6.200

6.  COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke.

Authors:  Peter Kraft; Tobias Schwarz; Lionel Pochet; Guido Stoll; Christoph Kleinschnitz
Journal:  Exp Transl Stroke Med       Date:  2010-02-15

7.  Deficiency of vasodilator-stimulated phosphoprotein (VASP) increases blood-brain-barrier damage and edema formation after ischemic stroke in mice.

Authors:  Peter Kraft; Peter Michael Benz; Madeleine Austinat; Marc Elmar Brede; Kai Schuh; Ulrich Walter; Guido Stoll; Christoph Kleinschnitz
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

8.  Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration.

Authors:  Christoph Kleinschnitz; Henrike Grund; Kirstin Wingler; Melanie E Armitage; Emma Jones; Manish Mittal; David Barit; Tobias Schwarz; Christian Geis; Peter Kraft; Konstanze Barthel; Michael K Schuhmann; Alexander M Herrmann; Sven G Meuth; Guido Stoll; Sabine Meurer; Anja Schrewe; Lore Becker; Valérie Gailus-Durner; Helmut Fuchs; Thomas Klopstock; Martin Hrabé de Angelis; Karin Jandeleit-Dahm; Ajay M Shah; Norbert Weissmann; Harald H H W Schmidt
Journal:  PLoS Biol       Date:  2010-09-21       Impact factor: 8.029

9.  Factor XII and uPAR upregulate neutrophil functions to influence wound healing.

Authors:  Evi X Stavrou; Chao Fang; Kara L Bane; Andy T Long; Clément Naudin; Erdem Kucukal; Agharnan Gandhi; Adina Brett-Morris; Michele M Mumaw; Sudeh Izadmehr; Alona Merkulova; Cindy C Reynolds; Omar Alhalabi; Lalitha Nayak; Wen-Mei Yu; Cheng-Kui Qu; Howard J Meyerson; George R Dubyak; Umut A Gurkan; Marvin T Nieman; Anirban Sen Gupta; Thomas Renné; Alvin H Schmaier
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

10.  Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy.

Authors:  Dirk Westermann; Thomas Walther; Konstantinos Savvatis; Felcicitas Escher; Meike Sobirey; Alexander Riad; Michael Bader; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Diabetes       Date:  2009-03-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.